These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32398107)

  • 1. Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon.
    Fokam J; Nangmo A; Wandum C; Takou D; Santoro MM; Nlend AN; Ateba FN; Ndombo PK; Kamgaing N; Kamta C; Essiane A; Lambo V; Fokunang C; Mbanya D; Colizzi V; Perno CF; Ndjolo A
    AIDS Res Ther; 2020 May; 17(1):14. PubMed ID: 32398107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring HIV Drug Resistance Early Warning Indicators in Cameroon: A Study Following the Revised World Health Organization Recommendations.
    Fokam J; Elat JB; Billong SC; Kembou E; Nkwescheu AS; Obam NM; Essiane A; Torimiro JN; Ekanmian GK; Ndjolo A; Shiro KS; Bissek AC
    PLoS One; 2015; 10(6):e0129210. PubMed ID: 26083364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the World Health Organization's HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in Namibia.
    Mutenda N; Bukowski A; Nitschke AM; Nakanyala T; Hamunime N; Mekonen T; Tjituka F; Mazibuko G; Mwinga S; Mabirizi D; Sagwa E; Indongo R; Dean N; Jordan MR; Hong SY
    PLoS One; 2016; 11(12):e0166649. PubMed ID: 27906995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon.
    Fokam J; Takou D; Njume D; Pabo W; Santoro MM; Njom Nlend AE; Beloumou G; Sosso S; Moudourou S; Teto G; Dambaya B; Djupsa S; Tetang Ndiang S; Ateba FN; Billong SC; Kamta C; Bala L; Lambo V; Tala V; Chenwi Ambe C; Mpouel ML; Cappelli G; Cham F; Ndip R; Mbuagbaw L; Koki Ndombo P; Ceccherini-Silberstein F; Colizzi V; Perno CF; Ndjolo A
    HIV Med; 2021 Aug; 22(7):567-580. PubMed ID: 33792134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study).
    Fokam J; Santoro MM; Takou D; Njom-Nlend AE; Ndombo PK; Kamgaing N; Kamta C; Essiane A; Sosso SM; Ndjolo A; Colizzi V; Perno CF
    BMC Pediatr; 2019 Jul; 19(1):226. PubMed ID: 31277610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon.
    Fokam J; Takou D; Teto G; Nforbih SE; Kome OP; Santoro MM; Ngoufack ES; Eyongetah M; Palmer D; Fokunang ET; Fokunang CN; Colizzi V; Perno CF; Ndjolo A
    PLoS One; 2020; 15(7):e0235958. PubMed ID: 32692778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".
    Fokam J; Sosso SM; Yagai B; Billong SC; Djubgang Mbadie RE; Kamgaing Simo R; Edimo SV; Nka AD; Tiga Ayissi A; Yimga JF; Takou D; Moudourou S; Ngo Nemb M; Nfetam Elat JB; Santoro MM; Perno CF; Colizzi V; Ndjolo A
    AIDS Res Ther; 2019 Nov; 16(1):36. PubMed ID: 31744517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based monitoring of HIV drug resistance early warning indicators in Uganda: A nationally representative survey following revised WHO recommendations.
    Asio J; Watera C; Namuwenge N; Kirungi W; Musinguzi J; Mugagga K; Busobozi R; Tusiime BJ; Lutalo T; Mbidde EK; Kaleebu P;
    PLoS One; 2020; 15(4):e0230451. PubMed ID: 32287264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of poor retention on antiretroviral therapy as a major HIV drug resistance early warning indicator in Cameroon: results from a nationwide systematic random sampling.
    Billong SC; Fokam J; Penda CI; Amadou S; Kob DS; Billong EJ; Colizzi V; Ndjolo A; Bisseck AZ; Elat JN
    BMC Infect Dis; 2016 Nov; 16(1):678. PubMed ID: 27846809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of Viral Non-Suppression and Acquired HIV-1 Drug Resistance Emergence among Children during the Sociopolitical Crisis in the Northwest Region of Cameroon: A Call for Improved Monitoring Strategies.
    Ayokanmi M; Fokam J; Tchidjou HK; Chenwi CA; Hortense GK; Kamgaing N; Takou D; Beloumou GA; Semengue E; Djupsa S; Nka AD; Teto G; Dambaya B; Sosso SM; Santoro MM; Ceccherini-Silberstein F; Awoh RA; Ekane GEH; Bissek AZK; Ndembi N; Colizzi V; Mbanya D; Perno CF; Ndjolo A
    Curr HIV Res; 2024; 22(5):336-348. PubMed ID: 39377407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between mental disorders with detectable viral load and poor adherence to antiretroviral therapy among adolescents infected with Human Immunodeficiency Virus on follow-up at Chantal Biya Foundation, Cameroon.
    Ndongo FA; Kana R; Nono MT; Noah JYA; Ndzie P; Tejiokem MC; Biheng EH; Ndie J; Nkoa TA; Ketchaji A; Ngako JN; Penda CI; Bissek ACZ; Ndombo POK; Hawa HM; Msellati P; Lallemant M; Faye A
    J Epidemiol Popul Health; 2024 Apr; 72(2):202193. PubMed ID: 38523399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings.
    Fokam J; Billong SC; Bissek AC; Kembou E; Milenge P; Abessouguie I; Nkwescheu AS; Tsomo Z; Aghokeng AF; Ngute GD; Ndumbe PM; Colizzi V; Elat JB
    BMC Public Health; 2013 Apr; 13():308. PubMed ID: 23565992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV drug resistance early warning indicators in namibia with updated World Health Organization guidance.
    Jonas A; Sumbi V; Mwinga S; DeKlerk M; Tjituka F; Penney S; Jordan MR; Desta T; Tang AM; Hong SY
    PLoS One; 2014; 9(7):e100539. PubMed ID: 24988387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early warning indicators for HIV drug resistance in Cameroon during the year 2010.
    Billong SC; Fokam J; Nkwescheu AS; Kembou E; Milenge P; Tsomo Z; Dion GN; Aghokeng AF; Mpoudi EN; Ndumbe PM; Colizzi V; Elat Nfetam JB
    PLoS One; 2012; 7(5):e36777. PubMed ID: 22615810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTP-READY study.
    Fokam J; Mpouel Bala ML; Santoro MM; Takou D; Tala V; Beloumou G; Ngoufack ES; Chenwi C; Pabo Willy Leroi T; Njume D; Teto G; Dambaya B; Djupsa S; Sosso S; Ateba F; Kamta C; Bala L; Njom Nlend AE; Koki Ndombo P; Colizzi V; Perno CF; Ndjolo A
    HIV Med; 2022 Jul; 23(6):629-638. PubMed ID: 34951111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
    HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance.
    Billong SC; Fokam J; Aghokeng AF; Milenge P; Kembou E; Abessouguie I; Meva'a-Onglene FB; Bissek AC; Colizzi V; Mpoudi EN; Elat JB; Shiro KS
    PLoS One; 2013; 8(8):e72680. PubMed ID: 23991142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
    Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
    J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).
    Liégeois F; Eymard-Duvernay S; Boyer S; Maradan G; Kouanfack C; Domyeum J; Boyer V; Mpoudi-Ngolé E; Spire B; Delaporte E; Vidal L; Kuaban C; Laurent C;
    HIV Med; 2019 Jan; 20(1):38-46. PubMed ID: 30362279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.